Galectin Therapeutics (GALT) Total Current Liabilities (2010 - 2026)

Galectin Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $7.3 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 93.41% year-over-year to $7.3 million in Q1 2026; TTM through Mar 2026 was $7.3 million, a 93.41% decrease from a year earlier, with the FY2025 full-year figure at $8.0 million, down 77.32% from the prior year.
• Total Current Liabilities declined to $7.3 million in Q1 2026 per GALT's latest filing, from $8.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $136.4 million in Q3 2025 and bottomed at $7.3 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $11.5 million (2023), against an average of $26.6 million.
• Across the five-year window, Total Current Liabilities surged 777.38% in 2025 and tumbled 93.41% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $13.0 million in 2022, then gained by 20.47% to $15.7 million in 2023, then surged by 125.88% to $35.4 million in 2024, then tumbled by 77.32% to $8.0 million in 2025, then declined by 9.0% to $7.3 million in 2026.
• Per Business Quant, the three latest GALT Total Current Liabilities figures stand at $7.3 million (Q1 2026), $8.0 million (Q4 2025), and $136.4 million (Q3 2025).